|
OTC:
Speed breaking growth
Racing alongside the booming economy is the Indian OTC business.
But there are quite few hurdles ahead of the marathon, Katya
Naidu finds out
Upfront
Upcoming
Events
Zydus
enters the derma market
Zydus Cadila has acquired Mumbai-based, Liva Health-care,
a mid-sized, Indian pharma company with a derma focussed product
portfolio.
GSK
gets FDA nod for cancer drug
GlaxoSmithKline received an approval for Tykerb (lapatinib),
in combination with Xeloda (capecitabine), for the treatment
of patients with advanced or metastatic breast cancer whose
tumours over express HER2 and who have received prior therapy
including an anthracycline, a taxane, and trastuzumab.
Avesthagen
launches genome project
Avestha Gengraine Tech-nologies (Avesthagen) announced the
launch of the Avestagenome, a unique project to build a complete
genetic, genealogical and medical database of the Parsis.
Lupin
to market Cefpodoxime Proxetil in France
Lupin with its French regulatory agent Venipharm has received
the marketing approval for generic Cefpodoxime Proxetil 100
mg tablets in France.
GVK
Bio joins forces with INC research
GVK Biosciences has collaborated with North Carolina based
CRO INC Research to form INC GVK Bio.
Bristol-Myers
Squibb inflates R&D base in India
Bristol-Myers Squibb (BMS) has announced the expansion of
its R&D capabilities in India, which is an integral part
of the company's overall R&D global strategy of accessing
top-talent around the world in support of its goal of achieving
sustainable, cost-effective growth.
AstraZeneca
invests in Indian science
An AstraZeneca Foundation has restructured its funds for the
long term, to build upon its pioneering sponsorship work in
the future.
Elder
ties up with Spanish company
Elder Pharmaceuticals has entered into an alliance with Laboratorios
Farmaceuticos Rovi, SA of Spain to market advanced heparins
(anti-thrombotics) in India for treatment and prevention of
thrombo-embolic venous diseases like deep vein thrombosis
and pulmonary embolism.
'We
understand our clients' expectations'
Adrian Possumato, Global Manager, Pharmaceutical Market, Multisorb
Technologies, has worked closely with drug innovators and
generic pharmaceutical manufacturers to determine the best
selection of packaged sorbents to stabilise pharmaceutical
formulations. He chats with Nandini Patwardhan about the company
and its new offering.
Products
'Very
few labs focuss on cancer diagnostics'
Vivek Trikha, Head Diagnostics, Dabur Pharma, speaks to Arshiya
Khan about Dabur OncQuest and its offerings in oncology as
well as the incidence of the disease
Of
science and finance
"It takes biotechnologists to evolve biotechnology. The
driving force of this industry is not finance, its science,"
opined Dr Rajiv Datar, Director, Exogen and Biotechnology
Consultant, at a symposium organised by American Bio Industry
Alliance (ABIA) and Confederation of Indian Industry (CII).
Moving
towards prevention
“Prevention and diagnostics to be the focus area,”
opined international experts. With the number of diseases
scaling heights, awareness is becoming the need of the hour.
Understanding
valuations
The Indian industry is living in the times of mergers and
acquisitions. However, there is lot of criticism in and out
of the industry that most of M&A are not well executed
and over valued.
Heart
of the matter
Do doctors want drugs? Some do and some don't. This discussion
is in relation with relation to stents wherein the opinion
is quite divided on whether it's wiser to use a drug eluting
stent or a bare metal stent.
|
